New options with dabigatran etexilate in anticoagulant therapy.
Ontology highlight
ABSTRACT: Thrombosis, the localized clotting of blood, occurs in both the arterial and venous circulation, and has a major impact on health outcomes. The primary etiology of myocardial infarctions, and approximately 80% of strokes, is acute arterial thrombosis. In combination this represents the most common cause of death in the Western world, while the third leading cause of cardiovascular-associated death is venous thromboembolism. An understanding of the pathogenic changes in the vessel wall and the blood that result in thrombosis is crucial for developing safer and more effective antithrombotic drugs. Dabigatran etexilate belongs to a new class of direct thrombin inhibitors. Following oral administration, dabigatran reaches peak plasma concentrations within 2 hours, shows linear pharmacokinetics
SUBMITTER: Maegdefessel L
PROVIDER: S-EPMC2879296 | biostudies-literature | 2010 May
REPOSITORIES: biostudies-literature
ACCESS DATA